Good MorningEquity markets wavered on Wednesday following some stronger-than-expected inflation data and hawkish commentary from the FOMC. On the inflation front, the PPI index advanced at a 0.4% month-over-month pace to double the expectations and leave the YOY figure up 8.5% from last year and at record levels. In regard to the FOMC, the Fed released the minutes from the last meeting and reinforced the idea that interest rates will move higher and stay higher for the foreseeable future.
Today's big news will be the CPI index which is expected to cool a bit from last month. The takeaway from the PPI report, however, is that producer-level inflation is still running hot and underpinning gains in consumer-level inflation. In this scenario, the CPI may cool versus last month but it should be expected to remain high and/or accelerate over the next few months to half a year. Featured: 5 Stocks Poised to Soar Under Trump's Presidency (Ad) 
|
Politics | | | If the economy really is headed for a recession, the stock market may have still more to drop.
The S&P 500 came into this week having already plunged roughly 24% from its record high earlier this year. But history shows the average U.S. recession since 1947 has brought an even big... Read the Full Story |
|
|
Stocks | | |
Energy stocks aren’t done yet.
The market’s only winning sector (by a wide margin) in 2022 is showing signs of life again following a modest summer swoon.
Leading the charge are oil and gas producers big and small that are all but locks to finish the year as the S&P 500&rsq... Read the Full Story |
|
Politics | | | A wobbly day of trading on Wall Street ended with a modest pullback for stocks Wednesday as investors weighed a report showed that inflation remains very hot, likely paving the way for more aggressive interest rate hikes by the Federal Reserve.
A late-afternoon drop erased tentative g... Read the Full Story |
|
From Our Partners2025 is off to a turbulent start—markets are swinging wildly, inflation pressures remain high, and recession fears are creeping back into headlines.
But even in uncertain times, innovation doesn’t slow down.
In fact, artificial intelligence (AI) is accelerating faster than ever—creating new profit opportunities while the broader market struggles.
Our latest research reveals two AI stocks trading under $15 that could thrive even as volatility grows. These under-the-radar companies are positioned to ride the next wave of AI-driven demand—and they’re still flying below most investors’ radar. | | | 👉[Click here to access your FREE AI stocks report now.] |
|
Markets | | |
Apple (NASDAQ: AAPL) is increasingly witnessing stock downgrades, and analysts are increasingly worried that as the company’s forecasts for production come down from their previous estimates, revenue could in much slower than previously expected. The average price target is still around $180... Read the Full Story |
|
Stocks | | |
If the first week of October was any indication, equity investors are in for a volatile fourth quarter.
Last week, the major U.S. indices sprinted out of the gates only to limp back to the starting line by Friday. Good news on the labor market front was perceived as bad news for U.S. stocks ... Read the Full Story |
|
From Our PartnersREVEALED: $194 Trillion Trump Market Pattern
Trump fires off a tweet and stocks tank…
He gives a speech and the markets soar…
Now, a new Trump executive order is set to set off a wave worth a potential $194 trillion in the markets.
And Wall Street insider Larry Benedict says it could hand investors who missed out on Trump’s first term a second chance. | | | Click here to discover this exciting new trading pattern. |
|
Politics | | | A senior member of the British government has rejected suggestions that Prime Minister Liz Truss should step down after lawmakers from her own party criticized Truss for economic policies that have sparked turmoil on financial markets Read the Full Story |
|
Markets | | |
Pepsico (NASDAQ: PEP) has been lagging behind the broad market since the pandemic bottom but that may be about to change. The company’s performance may be tied to its high valuation, it trades near 24X earnings, but the valuation is well earned and the stock has many attractive qualities for... Read the Full Story |
|
Markets | | | Delta Air Lines reported a $695 million third-quarter profit Thursday as higher average fares this summer and a lucrative credit-card business more than offset higher fuel prices.
The airline forecast that revenue during the final three months of the year will top pre-pandemic levels.... Read the Full Story |
|
Politics | | | Tens of millions of older Americans are about to get what may be the biggest raise of their lifetimes.
On Thursday, the U.S. government is set to announce how big a percentage increase Social Security beneficiaries will see in monthly payments this upcoming year. It’s virtually certa... Read the Full Story |
|
Markets | | | A 7% move higher since the last week of September versus the 3% drop seen in the NASDAQ index should tell you a lot about the potential in Take-Two Interactive Software Inc. (NASDAQ: TTWO). It’s true that the video game maker has put in a tough year so far, with shares recently down 40% from J... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands. | | View Today's Stock Pick |
|
